Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. NIH Consensus Development Program, (2002), National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10–12, 2002. Hepatology, 36, S3–S20.Google Scholar
  2. Allen, M.I., Deslauriers, M., Andrews, C.W., Tipples, G.A., Walters, K.A., Tyrrell, D.L., Brown, N. and Condreay, L.D., (1998), Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology, 27, 1670–1677.PubMedGoogle Scholar
  3. Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., Bartholomeusz, A. and Locarnini, S., (2003), Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125, 292–297.PubMedGoogle Scholar
  4. Bartenschlager, R., Frese, M. and Pietschmann, T., (2004), Novel insights into hepatitis C virus replication and persistence. Adv Virus Res, 63, 71–180.PubMedGoogle Scholar
  5. Blindenbacher, A., Duong, F.H., Hunziker, L., Stutvoet, S.T., Wang, X., Terracciano, L., Moradpour, D., Blum, H.E., Alonzi, T., Tripodi, M., La Monica, N. and Heim, M.H., (2003), Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology, 124, 1465–1475.PubMedGoogle Scholar
  6. Bozdayi, A.M., Uzunalimoglu, O., Turkyilmaz, A.R., Aslan, N., Sezgin, O., Sahin, T., Bozdayi, G., Cinar, K., Pai, S.B., Pai, R., Bozkaya, H., Karayalcin, S., Yurdaydin, C. and Schinazi, R.F., (2003), YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat, 10, 256–265.PubMedGoogle Scholar
  7. Bronowicki, J.P., Ouzan, D., Asselah, T., Desmorat, H., Zarski, J.P., Foucher, J., Bourliere, M., Renou, C., Tran, A., Melin, P., Hezode, C., Chevalier, M., Bouvier-Alias, M., Chevaliez, S., Montestruc, F., Lonjon-Domanec, I. and Pawlotsky, J.M., (2006), Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology, 131, 1040–1048.PubMedGoogle Scholar
  8. Buckheit, R.W., Jr., (2004), Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin Investig Drugs, 13, 933–958.PubMedGoogle Scholar
  9. Cane, P.A., Mutimer, D., Ratcliffe, D., Cook, P., Beards, G., Elias, E. and Pillay, D., (1999), Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther, 4, 7–14.PubMedGoogle Scholar
  10. Carroll, S.S. and Olsen, D.B., (2006), Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets, 6, 17–29.PubMedGoogle Scholar
  11. Castera, L. and Pawlotsky, J.M., (2005), Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. MedGenMed, 7, 39.PubMedGoogle Scholar
  12. Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P. and De Ledinghen, V., (2005), Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 128, 343–350.PubMedGoogle Scholar
  13. Castet, V., Fournier, C., Soulier, A., Brillet, R., Coste, J., Larrey, D., Dhumeaux, D., Maurel, P. and Pawlotsky, J.M., (2002), Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol, 76, 8189–8199.PubMedGoogle Scholar
  14. Chang, T.T., Gish, R.G., de Man, R., Gadano, A., Sollano, J., Chao, Y.C., Lok, A.S., Han, K.H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R. and Apelian, D., (2006), A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 354, 1001–1010.PubMedGoogle Scholar
  15. Chevaliez, S., Brillet, R., Hezode, C., Dhumeaux, D. and Pawlotsky, J.M., (2005), Assessment of ribavirin mutagenic properties in vivo and the influence of interferon alpha-induced reduction of hepatitis C virus RNA load upon therapy. Hepatology, 42 (Suppl. 1), 679A.Google Scholar
  16. Chin, R., Shaw, T., Torresi, J., Sozzi, V., Trautwein, C., Bock, T., Manns, M., Isom, H., Furman, P. and Locarnini, S., (2001), In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (–)-beta-D-2,6-diaminopurine dioxolane and 2’-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother, 45, 2495–2501.PubMedGoogle Scholar
  17. Chong, Y., Stuyver, L., Otto, M.J., Schinazi, R.F. and Chu, C.K., (2003), Mechanism of antiviral activities of 3’-substituted l-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach. Antivir Chem Chemother, 14, 309–319.PubMedGoogle Scholar
  18. Clavel, F. and Hance, A.J., (2004), HIV drug resistance. N Engl J Med, 350, 1023–1035.PubMedGoogle Scholar
  19. Colonno, R.J., Rose, R.E., Baldick, C.J., Levine, S.M., Klesczewski, K. and Tenney, D.J., (2006a), High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J Hepatol, 44 (Suppl. 2), S182.Google Scholar
  20. Colonno, R.J., Rose, R.E., Pokornowski, K., Baldick, C.J., Klesczewski, K. and Tenney, D.J., (2006b), Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology, 44 (Suppl. 2), 229A.Google Scholar
  21. Crotty, S., Cameron, C.E. and Andino, R., (2001), RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA, 98, 6895–6900.PubMedGoogle Scholar
  22. Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R. and Cameron, C.E., (2000), The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med, 6, 1375–1379.PubMedGoogle Scholar
  23. Das, K., Xiong, X., Yang, H., Westland, C.E., Gibbs, C.S., Sarafianos, S.G. and Arnold, E., (2001), Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol, 75, 4771–4779.PubMedGoogle Scholar
  24. Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J. and Albrecht, J., (2003), Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38, 645–652.PubMedGoogle Scholar
  25. de Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., McIntyre, N., Mele, A., Paumgartner, G., Pietrangelo, A., Rodes, J., Rosenberg, W. and Valla, D., (2003), EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol, 39 (Suppl. 1), S3–S25.PubMedGoogle Scholar
  26. Delaney, W.E.t., Edwards, R., Colledge, D., Shaw, T., Furman, P., Painter, G. and Locarnini, S., (2002), Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 46, 3057–3060.PubMedGoogle Scholar
  27. Delaney, W.E.t., Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T.G., Isom, H.C., Bock, C.T., Manns, M.P., Trautwein, C. and Locarnini, S., (2001), Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother, 45, 1705–1713.PubMedGoogle Scholar
  28. Delaney, W.E.t., Ray, A.S., Yang, H., Qi, X., Xiong, S., Zhu, Y. and Miller, M.D., (2006), Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother, 50, 2471–2477.PubMedGoogle Scholar
  29. Delaney, W.E.t., Yang, H., Westland, C.E., Das, K., Arnold, E., Gibbs, C.S., Miller, M.D. and Xiong, S., (2003), The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol, 77, 11833–11841.PubMedGoogle Scholar
  30. Dent, B., Chin, R., Trautwein, C., Bock, T.C., Manns, M.P., Cleary, D., Furman, P. and Locarnini, S.A., (2000), Antiviral cross-resistance profiles of two novel antiviral agents, DAPD and L-FMAU, against nucleoside analogue resistant HBV. Hepatology, 32 (Suppl. 1), 457A.Google Scholar
  31. Dienstag, J.L., Goldin, R.D., Heathcote, E.J., Hann, H.W., Woessner, M., Stephenson, S.L., Gardner, S., Gray, D.F. and Schiff, E.R., (2003), Histological outcome during long-term lamivudine therapy. Gastroenterology, 124, 105–117.PubMedGoogle Scholar
  32. Dixit, N.M., Layden-Almer, J.E., Layden, T.J. and Perelson, A.S., (2004), Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 432, 922–924.PubMedGoogle Scholar
  33. Duarte, E.A., Novella, I.S., Weaver, S.C., Domingo, E., Wain-Hobson, S., Clarke, D.K., Moya, A., Elena, S.F., de la Torre, J.C. and Holland, J.J., (1994), RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis, 3, 201–214.PubMedGoogle Scholar
  34. Durantel, D., Carrouee-Durantel, S., Werle-Lapostolle, B., Brunelle, M.N., Pichoud, C., Trepo, C. and Zoulim, F., (2004), A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology, 40, 855–864.PubMedGoogle Scholar
  35. Eldrup, A.B., Allerson, C.R., Bennett, C.F., Bera, S., Bhat, B., Bhat, N., Bosserman, M.R., Brooks, J., Burlein, C., Carroll, S.S., Cook, P.D., Getty, K.L., MacCoss, M., McMasters, D.R., Olsen, D.B., Prakash, T.P., Prhavc, M., Song, Q., Tomassini, J.E. and Xia, J., (2004), Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem, 47, 2283–2295.PubMedGoogle Scholar
  36. Ferenci, P., Fried, M.W., Shiffman, M.L., Smith, C.I., Marinos, G., Goncales, F.L., Jr, Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Chaneac, M. and Reddy, K.R., (2005), Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol, 43, 425–433.PubMedGoogle Scholar
  37. Foy, E., Li, K., Sumpter, R., Jr., Loo, Y.M., Johnson, C.L., Wang, C., Fish, P.M., Yoneyama, M., Fujita, T., Lemon, S.M. and Gale, M., Jr., (2005), Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA, 102, 2986–2991.PubMedGoogle Scholar
  38. Foy, E., Li, K., Wang, C., Sumpter, R., Jr., Ikeda, M., Lemon, S.M. and Gale, M., Jr., (2003), Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science, 300, 1145–1148.PubMedGoogle Scholar
  39. Frese, M., Pietschmann, T., Moradpour, D., Haller, O. and Bartenschlager, R., (2001), Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol, 82, 723–733.PubMedGoogle Scholar
  40. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr, Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J. and Yu, J., (2002), Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347, 975–982.PubMedGoogle Scholar
  41. Fu, L. and Cheng, Y.C., (1998), Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in l(–)SddC (3TC) resistance. Biochem Pharmacol, 55, 1567–1572.PubMedGoogle Scholar
  42. Fu, L. and Cheng, Y.C., (2000), Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother, 44, 3402–3407.PubMedGoogle Scholar
  43. Gale, M., Jr, Blakely, C.M., Kwieciszewski, B., Tan, S.L., Dossett, M., Tang, N.M., Korth, M.J., Polyak, S.J., Gretch, D.R. and Katze, M.G., (1998), Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol, 18, 5208–5218.PubMedGoogle Scholar
  44. Gale, M., Jr and Foy, E.M., (2005), Evasion of intracellular host defence by hepatitis C virus. Nature, 436, 939–945.PubMedGoogle Scholar
  45. Gale, M., Jr, Kwieciszewski, B., Dossett, M., Nakao, H. and Katze, M.G., (1999), Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol, 73, 6506–6516.PubMedGoogle Scholar
  46. Ganem, D. and Prince, A.M., (2004), Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med, 350, 1118–1129.PubMedGoogle Scholar
  47. Gintowt, A.A., Germer, J.J., Mitchell, P.S. and Yao, J.D., (2005), Evaluation of the MagNA Pure LC used with the Trugene HBV Genotyping Kit. J Clin Virol, 34, 155–157.PubMedGoogle Scholar
  48. Gish, R.G., Leung, N.W., Wright, T.L., Trinh, H., Lang, W., Kessler, H.A., Fang, L., Wang, L.H., Delehanty, J., Rigney, A., Mondou, E., Snow, A. and Rousseau, F., (2002), Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother, 46, 1734–1740.PubMedGoogle Scholar
  49. Gopalsamy, A., Aplasca, A., Ciszewski, G., Park, K., Ellingboe, J.W., Orlowski, M., Feld, B. and Howe, A.Y., (2006), Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett, 16, 457–460.PubMedGoogle Scholar
  50. Gunther, S., Fischer, L., Pult, I., Sterneck, M. and Will, H., (1999), Naturally occurring variants of hepatitis B virus. Adv Virus Res, 52, 25–137.PubMedGoogle Scholar
  51. Guo, J.T., Bichko, V.V. and Seeger, C., (2001), Effect of alpha interferon on the hepatitis C virus replicon. J Virol, 75, 8516–8523.PubMedGoogle Scholar
  52. Hadziyannis, S.J., Sette, H., Jr, Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr, Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A. and Ackrill, A.M., (2004), Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 140, 346–355.PubMedGoogle Scholar
  53. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Ma, J., Brosgart, C.L., Borroto-Esoda, K., Arterburn, S. and Chuck, S.L., (2006), Long-term therapy with Adefovir Dipivoxil for HBeAg-negative chronic Hepatitis B for up to 5 years. Gastroenterology, 131, 1743–1751.PubMedGoogle Scholar
  54. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Wulfsohn, M.S., Xiong, S., Fry, J. and Brosgart, C.L., (2003), Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 348, 800–807.PubMedGoogle Scholar
  55. He, Y., Nakao, H., Tan, S.L., Polyak, S.J., Neddermann, P., Vijaysri, S., Jacobs, B.L. and Katze, M.G., (2002), Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol, 76, 9207–9217.PubMedGoogle Scholar
  56. Heim, M.H., Moradpour, D. and Blum, H.E., (1999), Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol, 73, 8469–8475.PubMedGoogle Scholar
  57. Hezode, C., Bouvier-Alias, M., Costentin, C., Medkour, F., Franc-Poole, E., Aalyson, M., Alam, J., Dhumeaux, D. and Pawlotsky, J.M., (2006), Effect of an IMPDH inhibitor, merimepodib (MMPD), assessed alone and in combination with ribavirin, on HCV replication: implications regarding ribavirin’s mechanism of action. Hepatology, 44 (Suppl. 2), 615A.Google Scholar
  58. Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R.E., Calleja, J.L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R.L., Yong, C.L., Nehmiz, G. and Steinmann, G.G., (2004), Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology, 127, 1347–1355.PubMedGoogle Scholar
  59. Hong, S.P., Kim, N.K., Hwang, S.G., Chung, H.J., Kim, S., Han, J.H., Kim, H.T., Rim, K.S., Kang, M.S., Yoo, W. and Kim, S.O., (2004), Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol, 40, 837–844.PubMedGoogle Scholar
  60. Hultgren, C., Milich, D.R., Weiland, O. and Sallberg, M., (1998), The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol, 79, 2381–2391.PubMedGoogle Scholar
  61. Hussain, M., Fung, S., Libbrecht, E., Sablon, E., Cursaro, C., Andreone, P. and Lok, A.S., (2006), Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol, 44, 1094–1097.PubMedGoogle Scholar
  62. Kim, H.S., Han, K.H., Ahn, S.H., Kim, E.O., Chang, H.Y., Moon, M.S., Chung, H.J., Yoo, W., Kim, S.O. and Hong, S.P., (2005), Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther, 10, 441–449.PubMedGoogle Scholar
  63. Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O’Malley, E.T., Harbeson, S.L., Rice, C.M., Murcko, M.A., Caron, P.R. and Thomson, J.A., (1996), Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 87, 343–355.PubMedGoogle Scholar
  64. Klumpp, K., Leveque, V., Le Pogam, S., Ma, H., Jiang, W.R., Kang, H., Granycome, C., Singer, M., Laxton, C., Hang, J.Q., Sarma, K., Smith, D.B., Heindl, D., Hobbs, C.J., Merrett, J.H., Symons, J., Cammack, N., Martin, J.A., Devos, R. and Najera, I., (2006), The novel nucleoside analog R1479 (4’-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem, 281, 3793–3799.PubMedGoogle Scholar
  65. Koch, U. and Narjes, F., (2006), Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets, 6, 31–41.PubMedGoogle Scholar
  66. Kukolj, G., McGibbon, G.A., McKercher, G., Marquis, M., Lefebvre, S., Thauvette, L., Gauthier, J., Goulet, S., Poupart, M.A. and Beaulieu, P.L., (2005), Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem, 280, 39260–39267.PubMedGoogle Scholar
  67. Lai, C.L., Dienstag, J., Schiff, E., Leung, N.W., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R. and Condreay, L., (2003), Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis, 36, 687–696.PubMedGoogle Scholar
  68. Lai, C.L., Gane, E., Hsu, C.W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E.J., Rasenack, J., Bzowej, N., Naoumov, N., Zeuzem, S., Di Bisceglie, A., Chao, G.C., Fielman-Constance, B.A. and Brown, N.A., (2006a), Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) versus lamivudine. Hepatology, 44 (Suppl. 1), 222A.Google Scholar
  69. Lai, C.L., Gane, E., Liaw, Y.F., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E.J., Rasenack, J., Bzowej, N., Naoumov, N., Chao, G., Constance, B.F. and Brown, N.A., (2005), Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study). Hepatology, 42 (Suppl. 1), 232A.Google Scholar
  70. Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R.C., Cross, A., Colonno, R. and Fernandes, L., (2006b), Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 354, 1011–1020.Google Scholar
  71. Lampertico, P., (2006), Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. J Hepatol, 45, 457–460.PubMedGoogle Scholar
  72. Lampertico, P., Marzano, A., Levrero, M., Santantonio, T., Di Marco, V., Brunetto, M., Andreone, P., Sagnelli, E., Fagiuoli, S., Mazzella, G., Raimondo, G., Gaeta, G. and Ascione, A., (2006), Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology, 44 (Suppl. 2), 693A.Google Scholar
  73. Lanford, R.E., Guerra, B., Lee, H., Averett, D.R., Pfeiffer, B., Chavez, D., Notvall, L. and Bigger, C., (2003), Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol, 77, 1092–1104.PubMedGoogle Scholar
  74. Lau, J.Y., Tam, R.C., Liang, T.J. and Hong, Z., (2002), Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology, 35, 1002–1009.PubMedGoogle Scholar
  75. Lawitz, E., Nguyen, T., Younes, Z., Santoro, J., Gitlin, N., McEniry, D., Chasen, R., Goff, J., Knox, S., Kleber, K., Belanger, B., Brown, N.A. and Dieterich, D.T., (2006), Valopicitabine (NM283) plus peg-interferon in treatment-naive hepatitis C patients with HCV genotype 1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology, 44 (Suppl. 2), 223A.Google Scholar
  76. Le Pogam, S., Jiang, W.R., Leveque, V., Rajyaguru, S., Ma, H., Kang, H., Jiang, S., Singer, M., Ali, S., Klumpp, K., Smith, D., Symons, J., Cammack, N. and Najera, I., (2006), In vitro selected Con1 subgenomic replicons resistant to 2’-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology, 351, 349–359.PubMedGoogle Scholar
  77. Lee, W.M., (1997), Hepatitis B virus infection. N Engl J Med, 337, 1733–1745.PubMedGoogle Scholar
  78. Leung, N.W., Lai, C.L., Chang, T.T., Guan, R., Lee, C.M. and Ng, K.Y., (2001), Extended lamivudine treatment inpatients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 33, 1527–1532.PubMedGoogle Scholar
  79. Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S. and Colonno, R.J., (2002), Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother, 46, 2525–2532.PubMedGoogle Scholar
  80. Li, K., Foy, E., Ferreon, J.C., Nakamura, M., Ferreon, A.C., Ikeda, M., Ray, S.C., Gale, M., Jr and Lemon, S.M., (2005), Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA, 102, 2992–2997.PubMedGoogle Scholar
  81. Liaw, Y.F., Chien, R.N., Yeh, C.T., Tsai, S.L. and Chu, C.M., (1999), Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 30, 567–572.PubMedGoogle Scholar
  82. Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., Tanwandee, T., Tao, Q.M., Shue, K., Keene, O.N., Dixon, J.S., Gray, D.F. and Sabbat, J., (2004), Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351, 1521–1531.PubMedGoogle Scholar
  83. Lin, C., Gates, C.A., Rao, B.G., Brennan, D.L., Fulghum, J.R., Luong, Y.P., Frantz, J.D., Lin, K., Ma, S., Wei, Y.Y., Perni, R.B. and Kwong, A.D., (2005), In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem, 280, 36784–36791.PubMedGoogle Scholar
  84. Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A. and Kwong, A.D., (2004), In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem, 279, 17508–17514.PubMedGoogle Scholar
  85. Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A. and Rice, C.M., (2005), Complete replication of hepatitis C virus in cell culture. Science, 309, 623–626.PubMedGoogle Scholar
  86. Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E.B., Liang, T.J., Mutimer, D., Pawlotsky, J.M. and Zoulim, F., (2004), Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther, 9, 679–693.PubMedGoogle Scholar
  87. Lok, A.S., Heathcote, E.J. and Hoofnagle, J.H., (2001), Management of hepatitis B: 2000—summary of a workshop. Gastroenterology, 120, 1828–1853.PubMedGoogle Scholar
  88. Lok, A.S., Lai, C.L., Leung, N., Yao, G.B., Cui, Z.Y., Schiff, E.R., Dienstag, J.L., Heathcote, E.J., Little, N.R., Griffiths, D.A., Gardner, S.D. and Castiglia, M., (2003), Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125, 1714–1722.PubMedGoogle Scholar
  89. Loo, Y.M., Owen, D.M., Li, K., Erickson, A.K., Johnson, C.L., Fish, P.M., Carney, D.S., Wang, T., Ishida, H., Yoneyama, M., Fujita, T., Saito, T., Lee, W.M., Hagedorn, C.H., Lau, D.T., Weinman, S.A., Lemon, S.M. and Gale, M., Jr., (2006), Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA, 103, 6001–6006.PubMedGoogle Scholar
  90. Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T. and Hostomska, Z., (1996), The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell, 87, 331–342.PubMedGoogle Scholar
  91. Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H. and Molla, A., (2004), Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother, 48, 2260–2266.PubMedGoogle Scholar
  92. Lutchman, G.A., Danehower, S., Park, Y., Ward, C., Liang, T.J., Hoofnagle, J.H., Thomson, M.Z. and Ghany, M.G., (2004), Mutation rate of hepatitis C virus in patients during ribavirin monotherapy. Hepatology, 40 (Suppl. 1), 385A.Google Scholar
  93. Macdonald, A., Crowder, K., Street, A., McCormick, C., Saksela, K. and Harris, M., (2003), The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem, 278, 17775–17784.PubMedGoogle Scholar
  94. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M. and Albrecht, J.K., (2001), Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965.PubMedGoogle Scholar
  95. Marcellin, P., Chang, T.T., Lim, S.G., Tong, M.J., Sievert, W., Shiffman, M.L., Jeffers, L., Goodman, Z., Wulfsohn, M.S., Xiong, S., Fry, J. and Brosgart, C.L., (2003), Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 348, 808–816.PubMedGoogle Scholar
  96. Martell, M., Esteban, J.I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J. and Gomez, J., (1992), Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol, 66, 3225–3229.PubMedGoogle Scholar
  97. McHutchison, J.G., Shiffman, M.L., Gordon, S.C., Lindsay, K.L., Morgan, T., Norkrans, G., Esteban-Mur, R., Poynard, T., Pockros, P.J., Albrecht, J.K. and Brass, C., (2006), Sustained virologic response (SVR) to interferon-alpha-2b +/– ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up. J Hepatol, 44 (Suppl. 2), S275.Google Scholar
  98. Migliaccio, G., Tomassini, J.E., Carroll, S.S., Tomei, L., Altamura, S., Bhat, B., Bartholomew, L., Bosserman, M.R., Ceccacci, A., Colwell, L.F., Cortese, R., De Francesco, R., Eldrup, A.B., Getty, K.L., Hou, X.S., LaFemina, R.L., Ludmerer, S.W., MacCoss, M., McMasters, D.R., Stahlhut, M.W., Olsen, D.B., Hazuda, D.J. and Flores, O.A., (2003), Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem, 278, 49164–49170.PubMedGoogle Scholar
  99. Mo, H., Lu, L., Pilot-Matias, T., Pithawalla, R., Mondal, R., Masse, S., Dekhtyar, T., Ng, T., Koev, G., Stoll, V., Stewart, K.D., Pratt, J., Donner, P., Rockway, T., Maring, C. and Molla, A., (2005), Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother, 49, 4305–4314.PubMedGoogle Scholar
  100. Murakami, E., Bao, H., Ramesh, M., McBrayer, T.R., Whitaker, T., Micolochick Steuer, H.M., Schinazi, R.F., Stuyver, L.J., Obikhod, A., Otto, M.J. and Furman, P.A., (2006), Mechanism of activation of beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother, 51, 503–509.PubMedGoogle Scholar
  101. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. and Perelson, A.S., (1998), Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282, 103–107.PubMedGoogle Scholar
  102. Niesters, H.G., De Man, R.A., Pas, S.D., Fries, E. and Osterhaus, A.D., (2002), Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol, 51, 695–699.PubMedGoogle Scholar
  103. Nowak, M.A., Bonhoeffer, S., Hill, A.M., Boehme, R., Thomas, H.C. and McDade, H., (1996), Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA, 93, 4398–4402.PubMedGoogle Scholar
  104. O’Brien, C., Godofsky, E., Rodriguez-Torres, M., Afdhal, N.H., Pappas, S.C., Pockros, P., Lawitz, E., Bzowej, N., Rustgi, V., Sulkowski, M.S., Sherman, K.E., Jacobson, I.M., Chao, G., Knox, S., Pietropaolo, K. and Brown, N.A., (2005), Randomized trial of valopicitabine (NM283), alone or with peginterferon, vs retreatment with peginterferon plus ribavirin in hepatitis C patients with previous non response to peginterferon-ribavirin: first interim results. Hepatology, 42 (Suppl. 1), 234A.Google Scholar
  105. Ono, S.K., Kato, N., Shiratori, Y., Kato, J., Goto, T., Schinazi, R.F., Carrilho, F.J. and Omata, M., (2001), The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Investig, 107, 449–455.PubMedGoogle Scholar
  106. Osiowy, C., Villeneuve, J.P., Heathcote, E.J., Giles, E. and Borlang, J., (2006), Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol, 44, 1994–1997.PubMedGoogle Scholar
  107. Pallier, C., Castera, L., Soulier, A., Hezode, C., Nordmann, P., Dhumeaux, D. and Pawlotsky, J.M., (2006a), Dynamics of hepatitis B virus resistance to lamivudine. J Virol, 80, 643–653.Google Scholar
  108. Pallier, C., Rodriguez, C., Brillet, R. and Pawlotsky, J.M., (2006b), Dynamics of hepatitis B virus resistance to adefovir dipivoxil unraveled by a thorough quasispecies analysis. Hepatology, 44 (Suppl. 2), 565A.Google Scholar
  109. Papatheodoridis, G.V., Dimou, E., Laras, A., Papadimitropoulos, V. and Hadziyannis, S.J., (2002), Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology, 36, 219–226.PubMedGoogle Scholar
  110. Pawlotsky, J.M., (2002), Molecular diagnosis of viral hepatitis. Gastroenterology, 122, 1554–1568.PubMedGoogle Scholar
  111. Pawlotsky, J.M., (2003), Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res, 59, 1–11.PubMedGoogle Scholar
  112. Pawlotsky, J.M., (2005a), Current and future concepts in hepatitis C therapy. Semin Liver Dis, 25, 72–83.Google Scholar
  113. Pawlotsky, J.M., (2005b), The concept of hepatitis B virus mutant escape. J Clin Virol, 34 (Suppl. 1), S125–S129.Google Scholar
  114. Pawlotsky, J.M., (2006a), Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol, 299, 261–284.Google Scholar
  115. Pawlotsky, J.M., (2006b), Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43, S207–S220.Google Scholar
  116. Pawlotsky, J.M., Dahari, H., Neumann, A.U., Hezode, C., Germanidis, G., Lonjon, I., Castera, L. and Dhumeaux, D., (2004), Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 126, 703–714.PubMedGoogle Scholar
  117. Pawlotsky, J.M. and Gish, R.G., (2006), Future therapies for hepatitis C. Antivir Ther, 11, 397–408.PubMedGoogle Scholar
  118. Pawlotsky, J.M., Hezode, C., Pellegrin, B., Soulier, A., von Wagner, M., Brouwer, J.T., Missale, G., Germanidis, G., Lurie, Y., Negro, F., Esteban, J., Hellstrand, K., Ferrari, C., Zeuzem, S., Schalm, S.W. and Neumann, A.U., (2002), Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology, 36, 291A.Google Scholar
  119. Pawlotsky, J.M. and McHutchison, J.G., (2004), Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, 27 February–1 March 2003. Hepatology, 39, 554–567.PubMedGoogle Scholar
  120. Penin, F., (2003), Structural biology of hepatitis C virus. Clin Liver Dis, 7, 1–21.PubMedGoogle Scholar
  121. Peters, M., (1996), Actions of cytokines on the immune response and viral interactions: an overview. Hepatology, 23, 909–916.PubMedGoogle Scholar
  122. Polyak, S.J., Khabar, K.S., Paschal, D.M., Ezelle, H.J., Duverlie, G., Barber, G.N., Levy, D.E., Mukaida, N. and Gretch, D.R., (2001a), Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol, 75, 6095–6106.Google Scholar
  123. Polyak, S.J., Khabar, K.S., Rezeiq, M. and Gretch, D.R., (2001b), Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol, 75, 6209–6211.Google Scholar
  124. Poynard, T., Imbert-Bismut, F., Munteanu, M., Messous, D., Myers, R.P., Thabut, D., Ratziu, V., Mercadier, A., Benhamou, Y. and Hainque, B., (2004), Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol, 3, 8.PubMedGoogle Scholar
  125. Poynard, T., Imbert-Bismut, F., Munteanu, M. and Ratziu, V., (2005), FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn, 5, 15–21.Google Scholar
  126. Reesink, H., Forestier, N., Weegink, C., Zeuzem, S., McNair, L., Purdy, M., Chu, H.M. and Jansen, P.L.M., (2006a), Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950 in combination with peginterferon alpha-2a. J Hepatol, 44 (Suppl. 2), S272.Google Scholar
  127. Reesink, H.W., Zeuzem, S., Weegink, C.J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J. and Jansen, P.L., (2006b), Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology, 131, 997–1002.Google Scholar
  128. Reiser, M., Hinrichsen, H., Benhamou, Y., Reesink, H.W., Wedemeyer, H., Avendano, C., Riba, N., Yong, C.L., Nehmiz, G. and Steinmann, G.G., (2005), Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 41, 832–835.PubMedGoogle Scholar
  129. Richman, D.D., (1996), The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res, 29, 31–33.PubMedGoogle Scholar
  130. Richman, D.D., (2000), The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology, 32, 866–867.PubMedGoogle Scholar
  131. Richman, D.D., (2006), Contending with HBV resistance: lessons learned from HIV resistance and its management. Clinical Care Options, LLC, Atlanta, Georgia.Google Scholar
  132. Rodriguez-Torres, M., Lawitz, E., Muir, A.J., Keane, J., Kieffer, T.L., McNair, L. and McHutchison, J., (2006), Current status of subjects receiving peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology, 44 (Suppl. 2), 532A.Google Scholar
  133. Roque-Afonso, A.M., Ferey, M.P., Mackiewicz, V., Fki, L. and Dussaix, E., (2003), Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay. Antivir Ther, 8, 627–634.PubMedGoogle Scholar
  134. Sarrazin, C., Kieffer, T.L., Bartels, D., Hanzelka, B., Muh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H.M., Lin, C., Weegink, C., Reesink, H., Zeuzem, S. and Kwong, A.D., (2007a), Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology, 132, 1767–1777.Google Scholar
  135. Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S., Hussain, M., Shah, A., Cutler, D., Zhang, J. and Zeuzem, S., (2007b), SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon-a2b for genotype 1 non-responders. Gastroenterology, 132, 1270–1278.Google Scholar
  136. Schildgen, O., Sirma, H., Funk, A., Olotu, C., Wend, U.C., Hartmann, H., Helm, M., Rockstroh, J.K., Willems, W.R., Will, H. and Gerlich, W.H., (2006), Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 354, 1807–1812.PubMedGoogle Scholar
  137. Seigneres, B., Pichoud, C., Martin, P., Furman, P., Trepo, C. and Zoulim, F., (2002), Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology, 36, 710–722.PubMedGoogle Scholar
  138. Sertoz, R.Y., Erensoy, S., Pas, S., Akarca, U.S., Ozgenc, F., Yamazhan, T., Ozacar, T. and Niesters, H.G., (2005), Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother, 17, 514–520.PubMedGoogle Scholar
  139. Severini, A., Liu, X.Y., Wilson, J.S. and Tyrrell, D.L., (1995), Mechanism of inhibition of duck hepatitis B virus polymerase by (–)-beta-L-2’,3’-dideoxy-3’-thiacytidine. Antimicrob Agents Chemother, 39, 1430–1435.PubMedGoogle Scholar
  140. Shaw, T., Bartholomeusz, A. and Locarnini, S., (2006), HBV drug resistance: mechanisms, detection and interpretation. J Hepatol, 44, 593–606.PubMedGoogle Scholar
  141. Sheldon, J., Camino, N., Rodes, B., Bartholomeusz, A., Kuiper, M., Tacke, F., Nunez, M., Mauss, S., Lutz, T., Klausen, G., Locarnini, S. and Soriano, V., (2005), Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther, 10, 727–734.PubMedGoogle Scholar
  142. Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y.F., Cianciara, J., Boron-Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., Cross, A., Denisky, G., Kreter, B. and Hindes, R., (2006), Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 130, 2039–2049.PubMedGoogle Scholar
  143. Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspe, G., Kuiken, C., Maertens, G., Mizokami, M., Murphy, D.G., Okamoto, H., Pawlotsky, J.M., Penin, F., Sablon, E., Shin, I.T., Stuyver, L.J., Thiel, H.J., Viazov, S., Weiner, A.J. and Widell, A., (2005), Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 42, 962–973.PubMedGoogle Scholar
  144. Stuyver, L.J., Locarnini, S.A., Lok, A., Richman, D.D., Carman, W.F., Dienstag, J.L. and Schinazi, R.F., (2001), Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology, 33, 751–757.PubMedGoogle Scholar
  145. Stuyver, L.J., McBrayer, T.R., Tharnish, P.M., Clark, J., Hollecker, L., Lostia, S., Nachman, T., Grier, J., Bennett, M.A., Xie, M.Y., Schinazi, R.F., Morrey, J.D., Julander, J.L., Furman, P.A. and Otto, M.J., (2006), Inhibition of hepatitis C replicon RNA synthesis by beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother, 17, 79–87.PubMedGoogle Scholar
  146. Sumpter, R., Jr., Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M. and Gale, M., Jr., (2005), Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol, 79, 2689–2699.PubMedGoogle Scholar
  147. Tan, S.L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P., Jacobs, B.L., Mayer, B.J. and Katze, M.G., (1999), NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA, 96, 5533–5538.PubMedGoogle Scholar
  148. Taylor, D.R., Shi, S.T., Romano, P.R., Barber, G.N. and Lai, M.M., (1999), Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science, 285, 107–110.PubMedGoogle Scholar
  149. Tenney, D.J., Levine, S.M., Rose, R.E., Walsh, A.W., Weinheimer, S.P., Discotto, L., Plym, M., Pokornowski, K., Yu, C.F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S. and Colonno, R.J., (2004), Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother, 48, 3498–3507.PubMedGoogle Scholar
  150. Tenney, D.J., Rose, R.E., Baldick, C.J., Levine, S.M., Pokornowski, K.A., Walsh, A.W., Fang, J., Yu, C.F., Zhang, S., Mazzucco, C.M., Eggers, B., Hsu, M., Plym, M.J., Poundstone, P., Yang, J. and Colonno, R.J., (2007), Two-year entecavir resistance assessment in lamivudine refractory HBV patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother, 51, 902–911.PubMedGoogle Scholar
  151. Tilg, H., (1997), New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology, 112, 1017–1021.PubMedGoogle Scholar
  152. Tomassini, J.E., Getty, K., Stahlhut, M.W., Shim, S., Bhat, B., Eldrup, A.B., Prakash, T.P., Carroll, S.S., Flores, O., MacCoss, M., McMasters, D.R., Migliaccio, G. and Olsen, D.B., (2005), Inhibitory effect of 2’-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob Agents Chemother, 49, 2050–2058.PubMedGoogle Scholar
  153. Tomei, L., Altamura, S., Bartholomew, L., Biroccio, A., Ceccacci, A., Pacini, L., Narjes, F., Gennari, N., Bisbocci, M., Incitti, I., Orsatti, L., Harper, S., Stansfield, I., Rowley, M., De Francesco, R. and Migliaccio, G., (2003), Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol, 77, 13225–13231.PubMedGoogle Scholar
  154. Tomei, L., Altamura, S., Bartholomew, L., Bisbocci, M., Bailey, C., Bosserman, M., Cellucci, A., Forte, E., Incitti, I., Orsatti, L., Koch, U., De Francesco, R., Olsen, D.B., Carroll, S.S. and Migliaccio, G., (2004), Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol, 78, 938–946.PubMedGoogle Scholar
  155. Tong, X., Chase, R., Skelton, A., Chen, T., Wright-Minogue, J. and Malcolm, B.A., (2006), Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res, 70, 28–38.PubMedGoogle Scholar
  156. Tuttleman, J.S., Pourcel, C. and Summers, J., (1986), Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell, 47, 451–460.PubMedGoogle Scholar
  157. van Bommel, F., Wunsche, T., Mauss, S., Reinke, P., Bergk, A., Schurmann, D., Wiedenmann, B. and Berg, T., (2004), Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40, 1421–1425.PubMedGoogle Scholar
  158. Villeneuve, J.P., Durantel, D., Durantel, S., Westland, C., Xiong, S., Brosgart, C.L., Gibbs, C.S., Parvaz, P., Werle, B., Trepo, C. and Zoulim, F., (2003), Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol, 39, 1085–1089.PubMedGoogle Scholar
  159. Villet, S., Pichoud, C., Villeneuve, J.P., Trepo, C. and Zoulim, F., (2006), Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology, 131, 1253–1261.PubMedGoogle Scholar
  160. von Hahn, T., Evans, M.J., Syder, A.J., Hatziioannou, T., McKeating, J.A., Bieniasz, P.D. and Rice, C.M., (2006), Identification of claudin-1 as an essential cellular cell entry factor for hepatitis C virus. Hepatology, 44 (Suppl. 2), 197A.Google Scholar
  161. Wagoner, J., Austin, M., Green, J., Imaizumi, T., Casola, A., Brasier, A., Khabar, K.S., Wakita, T., Gale, M., Jr and Polyak, S.J., (2007), Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol, 81, 309–318.PubMedGoogle Scholar
  162. Walters, K.A., Tipples, G.A., Allen, M.I., Condreay, L.D., Addison, W.R. and Tyrrell, L., (2003), Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother, 47, 1936–1942.PubMedGoogle Scholar
  163. Westland, C., Delaney, W.t., Yang, H., Chen, S.S., Marcellin, P., Hadziyannis, S., Gish, R., Fry, J., Brosgart, C., Gibbs, C., Miller, M. and Xiong, S., (2003), Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology, 125, 107–116.PubMedGoogle Scholar
  164. Whalley, S.A., Murray, J.M., Brown, D., Webster, G.J., Emery, V.C., Dusheiko, G.M. and Perelson, A.S., (2001), Kinetics of acute hepatitis B virus infection in humans. J Exp Med, 193, 847–854.PubMedGoogle Scholar
  165. Yamamoto, T., Litwin, S., Zhou, T., Zhu, Y., Condreay, L., Furman, P. and Mason, W.S., (2002), Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2’-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol, 76, 1213–1223.PubMedGoogle Scholar
  166. Yan, Y., Li, Y., Munshi, S., Sardana, V., Cole, J.L., Sardana, M., Steinkuehler, C., Tomei, L., De Francesco, R., Kuo, L.C. and Chen, Z., (1998), Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci, 7, 837–847.PubMedGoogle Scholar
  167. Yang, H., Westland, C.E., Delaney, W.E.t., Heathcote, E.J., Ho, V., Fry, J., Brosgart, C., Gibbs, C.S., Miller, M.D. and Xiong, S., (2002), Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology, 36, 464–473.PubMedGoogle Scholar
  168. Yeon, J.E., Yoo, W., Hong, S.P., Chang, Y.J., Yu, S.K., Kim, J.H., Seo, Y.S., Chung, H.J., Moon, M.S., Kim, S.O., Byun, K.S. and Lee, C.H., (2006), Resistance to adefovir dipivoxil (ADV) in lamivudine-resistant chronic hepatitis B patients treated with ADV. Gut, 55, 1488–1495.PubMedGoogle Scholar
  169. Yi, M., Tong, X., Skelton, A., Chase, R., Chen, T., Prongay, A., Bogen, S.L., Saksena, A.K., Njoroge, F.G., Veselenak, R.L., Pyles, R.B., Bourne, N., Malcolm, B.A. and Lemon, S.M., (2006), Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem, 281, 8205–8215.PubMedGoogle Scholar
  170. Ying, C., De Clercq, E. and Neyts, J., (2000), Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat, 7, 79–83.PubMedGoogle Scholar
  171. Young, K.C., Lindsay, K.L., Lee, K.J., Liu, W.C., He, J.W., Milstein, S.L. and Lai, M.M., (2003), Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology, 38, 869–878.PubMedGoogle Scholar
  172. Yuen, M.F., Kato, T., Mizokami, M., Chan, A.O., Yuen, J.C., Yuan, H.J., Wong, D.K., Sum, S.M., Ng, I.O., Fan, S.T. and Lai, C.L., (2003), Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol, 39, 850–855.PubMedGoogle Scholar
  173. Zoulim, F., (2004), Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res, 64, 1–15.PubMedGoogle Scholar
  174. Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T.S., Liu, S.H., Trepo, C. and Cheng, Y.C., (1996), 2’,3’-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother, 40, 448–453.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Jean-Michel Pawlotsky

There are no affiliations available

Personalised recommendations